{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"33.9","upperLimit":"51.3","value":"42.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"132"}],"units":"Participants"}],"description":"Clinical benefit rate defined as percentage of patients with best overall response of CR, PR, or SD with a duration of at least 6 months. CR, PR, or SD were defined using RECIST, v1.1 criteria. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions. Percentage of participants = (participants with CR+PR+SD with a duration of at least 6 months /number of participants enrolled) \\*100.","dispersionType":"95% Confidence Interval","groups":[{"description":"200 mg abemaciclib given orally once every 12 hours for 28 days (1 cycle). Participants may continue to receive treatment until discontinuation criteria are met.","id":"OG000","title":"Abemaciclib"}],"paramType":"NUMBER","populationDescription":"All enrolled participants who received at least one dose of the study drug.","reportingStatus":"POSTED","timeFrame":"From Date of First Dose until Disease Progression or Death Due to Any Cause (Up To 14 Months)","title":"Percentage of Participants With Tumor Response of Stable Disease (SD) for at Least 6 Months, Partial Response (PR) or Complete Response (CR) (Clinical Benefit Rate)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}